uniQure
Meibergdreef 61
Amsterdam
1105 BA
Tel: 31-20-566-7394
Fax: 31-20-566-9272
Website: http://www.uniqure.com/
Email: info@uniQure.com
139 articles with uniQure
-
CSL Behring Announces Closing of Global Commercialization and License Agreement with uniQure for etranacogene dezaparvovec
5/6/2021
Global biotherapeutics leader CSL Behring announced the closing of its global Commercialization and License agreement with uniQure for etranacogene dezaparvovec, a novel gene therapy for the treatment of hemophilia B. Etranacogene dezaparvovec is currently in Phase 3 clinical trials and has been shown to result in near-normal levels of Factor IX – the blood clotting protein lacking in people with hemophilia B. CSL Behring has been recognized as a global hematology leader for decades.
-
Clinical Catch-Up: April 26-30
5/3/2021
Although clinical trial news related to COVID-19 was slow last week, there’s quite a bit of news on studies for other indications. -
There is hope for uniQure’s HOPE-B trial after all. Shares of uniQure NV are climbing this morning after the company announced the clinical hold on its hemophilia B gene therapy has been lifted by the U.S. Food and Drug Administration.
-
Clinical Catch-Up: March 29-April 2
4/5/2021
It was a busy week for clinical trial news. Here’s a look. -
An investigation was conducted by an independent laboratory and reviewed by leading external experts in the field.
-
The FDA put a clinical hold on UniQure's Phase III trial after a high-risk participant developed liver cancer.
-
In a shining moment that signaled hope for hemophilia B patients, uniQure presented data on Tuesday showing that its gene therapy treatment, etranacogene dezaparvovec (AMT-061), substantially increased production of the blood-clotting protein factor IX in nearly all pivotal Phase III HOPE-B trial...
-
Positive top-line data from UniQure’s Phase III HOPE-B gene therapy trial of etranacogene dezaparvove, an investigational AAV5-based gene therapy, point to a potentially curative treatment for patients with moderate to moderately severe hemophilia B.
-
In June, it dosed its first two patients using a novel therapeutic, AMT-130, delivered directly to the brain. Initial readouts are expected in a year’s time.
-
uniQure Announces Publication of Positive Interim Data from Phase IIb Clinical Trial of Etranacogene Dezaparvovec
10/31/2019
uniQure N.V. announced the publication of 26-week interim data from the ongoing Phase IIb clinical trial of etranacogene dezaparvovec, an investigational gene therapy for hemophilia B, in the journal, Blood Advances.
-
BioSpace Global Roundup, Sept. 5
9/5/2019
Companies from across Europe and Asia share updates on their business and pipelines. -
uniQure Announces Achievement of Planned Enrollment in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Patients with Hemophilia B
9/3/2019
uniQure N.V. announced that the planned enrollment of 56 patients has been achieved in the HOPE-B pivotal trial of etranacogene dezaparvovec, an investigational AAV5-based gene therapy incorporating the patent-protected FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B.
-
BioSpace Global Roundup, July 11
7/11/2019
Companies from across Europe, Asia and around the globe share pipeline and business updates. -
uniQure Announces 36 Weeks of Follow-Up Data from Phase IIb Study of AMT-061 and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B
7/6/2019
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced updated clinical data on the three patients treated in the Company’s ongoing Phase IIb study of AMT-061, an investigational AAV5-based gene therapy containing a patent-protected FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B
-
A report about Amsterdam-based uniQure indicated it is looking at various options, including a potential sale. As a result, company stock jumped as much as 10% in premarket trading.
-
April 17, 2019 is the 29th World Hemophilia Day, a designated day to create awareness of the disease. Hemophilia is one of a number of bleeding disorders. The blood of people with hemophilia does not clot normally as the result of insufficient clotting factor. As a result, they can bleed for a lo...
-
After Earlier Dramatic Gene Therapy Collapse, uniQure's Hemophilia B Therapy Showing Promise
2/8/2019
Based in Lexington, Mass. and Amsterdam, The Netherlands, uniQure updated its Phase IIb trial of AMT-061 in hemophilia B. AMT-061 is an AAV5-based gene therapy that contains a FIX-Padua variant, meaning a patent-protected form of Factor IX, the missing or insufficient protein that results in the ... -
Across the globe, pharma companies are making an impact. Last week BioSpace launched the first of a weekly roundup of international biotech and pharma news. Here's the latest edition.
-
uniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
8/23/2018
uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced that it has treated the first patient in its Phase IIb dose-confirmation study of AMT-061, an investigational AAV5-based gene therapy incorporating the FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B.
-
uniQure Announces Second Quarter 2018 Financial Results and Highlights Company Progress
8/8/2018
Patient Enrollment Underway in Global Phase III HOPE-B Pivotal Study of AMT-061